On Friday, Syndax Pharmaceuticals Inc (NASDAQ: SNDX) opened lower -0.90% from the last session, before settling in for the closing price of $19.89. Price fluctuations for SNDX have ranged from $11.22 to $25.34 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 1801.91% annually for the last half of the decade. Company’s average yearly earnings per share was noted -25.85% at the time writing. With a float of $79.45 million, this company’s outstanding shares have now reached $84.83 million.
In an organization with 184 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -1005.33%, operating margin of -7135.53%, and the pretax margin is -6543.16%.
Syndax Pharmaceuticals Inc (SNDX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Syndax Pharmaceuticals Inc is 6.64%, while institutional ownership is 97.20%. The most recent insider transaction that took place on Jun 14 ’24, was worth 25,037. In this transaction Chief Financial Officer of this company bought 1,250 shares at a rate of $20.03, taking the stock ownership to the 52,623 shares.
Syndax Pharmaceuticals Inc (SNDX) Latest Financial update
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.73 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.79) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.96 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -25.85% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.50% during the next five years compared to -0.41% drop over the previous five years of trading.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Trading Performance Indicators
Check out the current performance indicators for Syndax Pharmaceuticals Inc (SNDX). In the past quarter, the stock posted a quick ratio of 10.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 479.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.38, a number that is poised to hit -1.13 in the next quarter and is forecasted to reach -3.24 in one year’s time.
Technical Analysis of Syndax Pharmaceuticals Inc (SNDX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.72 million. That was inferior than the volume of 1.07 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 83.02%. Additionally, its Average True Range was 0.74.
During the past 100 days, Syndax Pharmaceuticals Inc’s (SNDX) raw stochastic average was set at 30.66%, which indicates a significant decrease from 78.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.03% in the past 14 days, which was lower than the 43.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.32, while its 200-day Moving Average is $21.13. However, in the short run, Syndax Pharmaceuticals Inc’s stock first resistance to watch stands at $20.11. Second resistance stands at $20.50. The third major resistance level sits at $20.84. If the price goes on to break the first support level at $19.38, it is likely to go to the next support level at $19.04. The third support level lies at $18.65 if the price breaches the second support level.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Key Stats
There are currently 84,987K shares outstanding in the company with a market cap of 1.68 billion. Presently, the company’s annual sales total 0 K according to its annual income of -209,360 K. Last quarter, the company’s sales amounted to 3,500 K and its income totaled -68,060 K.
